- Solutions
Our solutions
- OverviewOur workflow solutions give you the data, tools, and insights to power every decision
- Strategic IntelligenceGet a complete view of strategic issues and stay ahead of emerging disruptive themes
- Sales IntelligenceOur workflow solutions give you the data, tools, and insights to power every decision
- Industry
- Platform
Our platform
Your powerful intelligence platform
Explore the fully comprehensive productivity and insights platform
- Company
We are GlobalData
The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences for the mental health of women with major depressive disorder (MDD), which is expected to increase in prevalence after the pandemic, says GlobalData, a leading data and analytics company. Ana Fernandez Menjivar, MSc DLSHTM, Senior Epidemiologist at GlobalData, comments: “The higher prevalence of MDD […]
Non-alcoholic fatty liver disease inclusion into national prevention program likely to reduce NASH prevalence in India, says GlobalData
Non-alcoholic fatty liver disease (NAFLD) is emerging as an important cause of a wide spectrum of liver diseases including non-alcoholic steatohepatitis (NASH) in India. A proactive focus on NAFLD if translated into action can halt its prognosis to NASH, thereby reducing its prevalence in the country, says GlobalData, a leading data and analytics company. In […]
Although Novartis’ Kesimpta can be self-administered, it will not be market leader currently, says GlobalData
Following the news that the European Medicines Agency (EMA) has approved Novartis’ Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults; Philippa Salter, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Kesimpta will provide a point of difference for MS patients as the first B-cell […]
AbbVie is a strong contender for migraine market following accepted NDA from FDA for atogepant
Following today’s news (30 March) that the FDA has accepted AbbVie’s new drug application for atogepant for the preventive treatment of migraine; Christie Wong, Pharma Analyst at GlobalData, a leading data and analytics company offers her view: “If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed to reduce the […]
300% increase in number of companies conducting endometriosis clinical trials since 2010, says GlobalData
According to GlobalData’s clinical trial database, the landscape for endometriosis has greatly diversified in recent years. The number of companies initiating trials in the space rose from only three in 2010 to 12 in 2019 – an increase of 300% over the ten-year period. Fiona Chisholm, Pharma Analyst at GlobalData comments: “The endometriosis market is […]
Chemotherapy uptake to gradually decrease with arrival of novel therapies and biosimilars, says GlobalData
Negative CAGRs of 0.61% and 3.89% is projected for the chemotherapy drug class in the US market for haematological and solid tumors, respectively. Sales for chemotherapy in the 5EU expected to remain around $3.2bn over the next decade despite increased incidence of cancer. Trends in chemotherapy sales expected to vary widely with CAGRs ranging from […]
West China’s pharma manufacturing lagging behind other regions, observes GlobalData
Western China’s pharmaceutical production needs international and domestic investment, as there less number of facilities compared to other Chinese regions and few international pharma companies or CMOs in the region given its geographic size, says GlobalData, a leading data and analytics company Adam Bradbury, PharmSource Analyst at GlobalData, comments: “There may be limits on international […]
AstraZeneca’s and J&J’s COVID-19 vaccines manufacturing face viral vector shortages
The latest wave of COVID-19 vaccines – those from AstraZeneca and Johnson & Johnson (J&J) – are recombinant vector vaccines, which are a different molecule type from the first wave of mRNA-based COVID-19 vaccines from Pfizer/BioNTech and Moderna. As recombinant vector vaccines use a virus as a vector for DNA delivery, they will be forced […]
Several US states are easing COVID-19 restrictions too early, says GlobalData
Texas and several other states such as Mississippi, Louisiana, and Michigan rescinding previous executive orders that were intended to slow the spread of COVID-19 could cause an emergence of more transmissible variants, says GlobalData, a leading data and analytics company. Walter Gabriel, MPH, Epidemiologist at GlobalData, comments: “The decision to ease restrictions comes in the […]
Accelerated deal-making activity promises delivery of late-stage clinical candidates in head and neck cancer, says GlobalData
Rising strategic partnerships between global pharmaceutical companies to develop therapies in the head and neck cancer space can serve as opportunities for increased scientific development and business collaborations, says GlobalData, a leading data and analytics company. Aarohi Rede, BDS, MPH, Oncology Analyst at GlobalData, comments: “The past few years have seen several licensing deals globally […]
There has been a 92% decrease in UK COVID-19 cases since January, says GlobalData
On March 7, 2021, the UK reported 5,265 daily confirmed cases, the lowest reported case count since the second-wave peak of over 68,000 cases on January 8, 2021. This 92% decrease in daily confirmed cases in just under two months is evidence of the effectiveness of the national lockdown, social distancing, and vaccinations, says GlobalData, […]
Cipla takes deal route with Alvotech to enter Australian autoimmune biosimilars market, says GlobalData
Australia continues to focus on reducing healthcare expenditure and encouraging the use of biosimilars over their reference product. Cipla adopted deals route to capitalize on the opportunities that exist within the Australian biosimilars space, says GlobalData, a leading data and analytics company. On 02 March 2021, Cipla Gulf and Alvotech expanded their partnership to market […]
Chronic kidney disease anemia drug market expected to grow to $6.6bn by 2029, according to GlobalData
The total chronic kidney disease (CKD) anemia drug market size for the 8MM* in 2019 was valued at $4.7bn, defined as sales of major branded and biosimilar drugs, as well as iron products that are commonly prescribed in CKD anemia patients. By 2029, CKD anemia drug sales across these markets are expected to grow to […]
Physicians eager to adopt new biomarkers for immuno-oncology regimens, finds GlobalData
The field of immuno-oncology (IO) has been in need of novel biomarkers ever since 2011. The most promising or anticipated biomarker among high-prescribing physicians in the seven major markets (7MM*) was identified to be measures of tumor mutational burden (TMB), according to GlobalData, a leading data and analytics company. Sakis Paliouras, PhD, Senior Oncology Analyst […]
Mylan’s merger with UpJohn as Viatris provides significant opportunity to focus on biosimilar launch and uptake
Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s Novolog/NovoRapid (insulin aspart); Samisha Khangaonkar, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “While Key Opinion Leaders (KOLs) interviewed by GlobalData are relatively brand agnostic when prescribing rapid-acting insulin analogs, there is a […]
China continues to dominate high value oncology strategic deals in Asia-Pacific, reveals GlobalData
High value deals have dominated the Asia-Pacific (APAC) pharmaceutical strategic partnership landscape in 2020. Within the region, China is well ahead of other countries, particularly in the field of oncology, reveals GlobalData, a leading data and analytics company. Ms. Sasmitha Sahu, Pharma Analyst at GlobalData, comments: “China has tackled the COVID-19 pandemic effectively and restarted […]
High number of COVID-19 cases in France and Italy possibly due to UK variant, says GlobalData
Italy and France are witnessing another wave of COVID-19 infections probably caused by the spread of the UK B.1.1.7 variant and the only realistic solution is to massively increase the daily vaccination rate, says GlobalData, a leading data and analytics company. Bishal Bhandari, PhD, Senior Epidemiologist at GlobalData, comments: “France and Italy had their COVID-19 […]
CRISPR-based cancer therapies have potential to be a disruptive technology in healthcare, according to GlobalData
Clustered regularly interspaced short palindromic repeat (CRISPR) therapies are one of the most potentially powerful and transformative technologies in human history, according to GlobalData, a leading data and analytics company. Expected to be able to prolong the life of cancer patients by decades, compared to the current performance of blockbuster drugs that prolong life by […]
Diagnosed prevalent cases of chronic kidney disease-anemia to reach 4.5 million by 2029 in the 8MM, says GlobalData
The diagnosed prevalent cases of chronic kidney disease-anemia (CKD-anemia) in the eight major markets (*8MM) are projected to increase from four million cases in 2019 to 4.5 million cases in 2029, equating to an annual growth rate (AGR) of 1.13%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Chronic Kidney Disease-Anemia – […]
Stellar progress has been made on vaccines at the one-year anniversary of COVID-19 in the US, says GlobalData
At the one-year anniversary of the World Health Organization’s official declaration of the COVID-19 pandemic, there has been record-breaking progress made towards developing a COVID-19 vaccine and vaccination in the US. However, the threat that variants could reduce vaccine effectiveness remains, though recent results indicate that vaccines could still have a 100% efficacy against severe […]